BD FOX PCR Extraction Tubes; BD Onclarity HPV Assay
Becton Dickinson and Company · Decision date Feb 12, 2026
What did the FDA decide?
FDA records P160037/S026 as a supplement to PMA P160037, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 12, 2026.
FDA approval order statement
an internal building to building transfer of a manufacturing process
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Microbiology
- Decision date
- Feb 12, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P160037/S026
- Regulatory pathway
- PMA supplement
- Applicant
- Becton Dickinson and Company
- Product code
- MAQ
- Decision code
- OK30
- Decision date
- Feb 12, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS.
- Applicant
- Becton Dickinson and Company
- Product code
- MAQ
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P160037/S022 · Related supplement
BD ONCLARITY HPV ASSAY
P160037/S026 received
Application receipt date recorded by FDA.
P160037/S026 · FDA decision
30-Day Notice
P160037/S024 · Related supplement
BD Onclarity HPV Assay
P160037/S025 · Related supplement
BD Onclarity HPV Assay
P160037/S028 · Related supplement
BD Onclarity HPV Assay
P160037/S027 · Related supplement
BD Onclarity HPV Assay Reagent Pack (SKU 444075) and BD COR HPV Extraction Trough (SKU 444074)
Timeline entries are records held by MedtechLedger for P160037. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160037
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
BD ONCLARITY HPV ASSAYP160037/S022 | Becton Dickinson and Company | PMA supplement | Aug 25, 2025 | FDA |
BD Onclarity HPV AssayP160037/S024 | Becton Dickinson and Company | PMA supplement | Apr 2, 2026 | FDA |
BD Onclarity HPV AssayP160037/S025 | Becton Dickinson and Company | PMA supplement | Apr 2, 2026 | FDA |
BD Onclarity HPV AssayP160037/S028 | Becton Dickinson and Company | PMA supplement | Aug 14, 2026 | FDA |
| Becton Dickinson and Company | PMA supplement | Aug 19, 2026 | FDA |
Explore the linked device profile
Other records with product code MAQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
cobas HPVP100020/S066 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
cobas HPVP190028/S026 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Alinity m HR HPVP230003/S019 | Abbott Molecular, Inc. | PMA supplement | Sep 2, 2026 | FDA |
Alinity m HR HPVP230003/S015 | Abbott Molecular, Inc. | PMA supplement | Jul 23, 2026 | FDA |
Alinity m HR HPVP230003/S018 | Abbott Molecular, Inc. | PMA supplement | Jun 22, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Becton Dickinson and Company
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 7loveton Cir., Sparks, MD, 21152
Sources and methodology
- Original FDA record: P160037/S026
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records






